Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer

Published:2021 Issue:3 Volume:18 Page:849-859
ISSN:2095-3941
Container-title:Cancer Biology and Medicine
language:en
Short-container-title:Cancer Biol. Med.

Author:

Hu Nanlin,Si Yiran,Yue Jian,Sun Tingting,Wang Xue,Jia Zhuqing,Gao Songlin,Li Qiao,Shao Yang,Wang Jiayu,Luo Yang,Ma Fei,Xu Binghe,Yuan Peng

Publisher

Cancer Biology and Medicine

Subject

Cancer Research,Oncology

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating Tumor DNA and Survival in Metastatic Breast Cancer;JAMA Network Open;2024-09-05

2. Case report: outcome of anlotinib treatment in breast cancer patient with brain metastases;Frontiers in Pharmacology;2024-08-19

3. REThinking the role of the RET oncogene in breast cancer;Frontiers in Oncology;2024-08-01

4. Comprehensive analysis of the prognostic and immunological roles of HGH1 in breast cancer;Asian Journal of Surgery;2024-06

5. Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial;eClinicalMedicine;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP